Spectral Announces Status of Second Interim Analysis
News Jan 31, 2014
Spectral Diagnostics Inc. has announced that the Data Safety Monitoring Board (DSMB) has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days.
The DSMB has recommended that the trial continue, but has asked that further analysis be performed before recalculation of the trial's sample size is finalized.
"The Company will await the specifics of the DSMB report, expected soon, before determining next steps in its clinical and commercial pathway," said Dr. Paul Walker, President and CEO of Spectral Diagnostics.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
"Cell Quake Elastography" Maps Elasticity of Cell ComponentsNews
In somewhat the same way that seismologists use the vibrations of planet Earth to characterize its deep structure, scientists have discovered a way to use vibrations within cells to identify their mechanical properties.READ MORE